Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061

Journal of Virology
D ThibeaultDaniel Lamarre

Abstract

Hepatitis C virus (HCV) displays a high degree of genetic variability. Six genotypes and more than 50 subtypes have been identified to date. In this report, kinetic profiles were determined for NS3 proteases of genotypes 1a, 1b, 2ac, 2b, and 3a, revealing no major differences in activity. In vitro sensitivity studies with BILN 2061 showed a decrease in affinity for proteases of genotypes 2 and 3 (K(i), 80 to 90 nM) compared to genotype 1 enzymes (K(i), 1.5 nM). To understand the reduced sensitivity of genotypes 2 and 3 to BILN 2061, active-site residues in the proximity of the inhibitor binding site were replaced in the genotype-1b enzyme with the corresponding genotype-2b or -3a residues. The replacement of five residues at positions 78, 79, 80, 122, and 132 accounted for most of the reduced sensitivity of genotype 2b, while replacement of residue 168 alone could account for the reduced sensitivity of genotype 3a. BILN 2061 remains a potent inhibitor of these non-genotype-1 NS3-NS4A proteins, with K(i) values below 100 nM. This in vitro potency, in conjunction with the good pharmacokinetic data reported for humans, suggests that there is potential for BILN 2061 as an antiviral agent for individuals infected with non-genotype-1...Continue Reading

References

May 25, 1995·Biochemical and Biophysical Research Communications·N KakiuchiK Shimotohno
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·M Llinàs-BrunetD Lamarre
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·M Llinàs-BrunetD Lamarre
Jun 22, 1999·The Journal of Biological Chemistry·S R LaPlanteM Llinàs-Brunet
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·J W Drake, J J Holland
Dec 11, 1999·Current Topics in Microbiology and Immunology·K E Reed, C M Rice
Jan 6, 2000·Journal of Hepatology·P Simmonds
Jan 6, 2000·Journal of Hepatology·M U Mondelli, E Silini
Jul 13, 2000·Baillière's Best Practice & Research. Clinical Gastroenterology·G WebsterG Dusheiko
Oct 31, 2000·Bioorganic & Medicinal Chemistry Letters·M Llinàs-BrunetD Lamarre
Mar 21, 2001·The Journal of General Virology·P Simmonds
May 29, 2001·Current Medicinal Chemistry·C SteinkühlerV G Matassa
Mar 12, 2002·Virus Research·Esteban DomingoCristina Escarmis
Oct 31, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jay H Hoofnagle
Oct 31, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Adrian M Di Bisceglie, Jay H Hoofnagle
Mar 21, 2003·The Journal of Biological Chemistry·Arnim PauseDaniel Lamarre
Apr 15, 2003·Clinics in Liver Disease·Jean-Michel Pawlotsky
Aug 7, 2004·Journal of Chromatography. a·Peter A Tate, John G Dorsey

❮ Previous
Next ❯

Citations

Apr 16, 2013·Bioorganic & Medicinal Chemistry·Deena S LasheenKhaled A M Abouzid
Aug 19, 2005·Nature·Raffaele De Francesco, Giovanni Migliaccio
Dec 1, 2007·Nature Reviews. Drug Discovery·Erik De Clercq
Dec 29, 2012·The Journal of Biological Chemistry·Jeff A O'MearaMontse Llinàs-Brunet
Aug 30, 2008·The Journal of Biological Chemistry·Rudolf K F Beran, Anna Marie Pyle
Dec 29, 2009·Assay and Drug Development Technologies·Smitha KotaArthur Donny Strosberg
Oct 26, 2011·Antimicrobial Agents and Chemotherapy·Lisette LagacéGeorge Kukolj
Apr 27, 2007·Journal of Virology·Frederik PauwelsKenneth A Simmen
Jul 20, 2007·Journal of Bioinformatics and Computational Biology·Elena L MishchenkoNikolai A Kolchanov
Nov 19, 2013·Microbial Cell Factories·Muhammad Ikram AnwarMoazur Rahman
Oct 26, 2012·Virology Journal·Stefania PaolucciFausto Baldanti
Nov 1, 2009·Future Medicinal Chemistry·Phillip A FurmanEisuke Murakami
May 23, 2007·Proceedings of the National Academy of Sciences of the United States of America·Guofeng ChengFrancis V Chisari
May 19, 2006·Proceedings of the National Academy of Sciences of the United States of America·Guofeng ChengFrancis V Chisari
Sep 8, 2005·Expert Opinion on Investigational Drugs·Nathalie Goudreau, Montse Llinàs-Brunet
Jun 10, 2009·Biochimica Et Biophysica Acta·María Victoria FloresRomuald Corbau
Aug 28, 2007·Advanced Drug Delivery Reviews·Kohji Moriishi, Yoshiharu Matsuura
Mar 7, 2012·Pharmacotherapy·Olga M KlibanovShannon H Williams
May 1, 2010·Biochimie·Neil D Rawlings
Dec 1, 2009·Biochemical and Biophysical Research Communications·Marie-Josée MassariolPeter W White
May 27, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Norman M KnetemanDavid F Mercer
Feb 26, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Markus ReiserGerhard G Steinmann
Oct 16, 2004·The Journal of General Virology·Peter Simmonds
May 25, 2013·The Journal of Biological Chemistry·Noreena L SweeneyDavid N Frick
May 7, 2020·Journal of Advanced Research·Moustafa E El-ArabyMahmoud A Elfaky
Aug 19, 2010·Journal of Medicinal Chemistry·Montse Llinàs-BrunetPeter W White
Jan 29, 2014·Journal of Medicinal Chemistry·Steven R LaPlanteSteven J Taylor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.